(UroToday.com) In this presentation at the 2021 ASCO Genitourinary Cancers Symposium (ASCO GU) Dr. Peter Nelson discussed the evidence leading to the approval of the PARP inhibitors olaparib and rucaparib in advanced prostate cancer and then discussed issues surrounding biomarkers for patient selection.